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Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a
paracrine growth factor for cultured fibrosis-derived kidney fibroblasts.
We studied the role of interleukin-1 beta (IL-1f3) and basic fibroblast
growth factor (bFGF) in the proliferative response of transformed human
renal interstitial fibroblast cell lines established from either a kidney with
glomerulonephritis and interstitial fibrosis or a normal kidney in compar-
ison to primaiy human foreskin fibroblasts. Growth of fibrosis-derived
renal fibroblasts was inhibited in the presence of IL-i receptor antagonist
(IL-iRa) by 35% (P < 0.005), suggesting that these cells produce IL-i and
possess IL-i receptors as part of paracrine growth. In contrast, spontane-
ous proliferation of fibroblasts derived from a normal kidney or normal
skin were not inhibited by IL-iRa. In fibrosis-derived but not in normal
renal cells, fibronectin synthesis was increased 2.2-fold (P < 0.01) in the
presence of IL-iRa. Addition of exogenous IL-1f3 or bFGF stimulated
proliferation of skin fibroblasts. In contrast, growth of fibrosis-derived
renal fibroblasts was stimulated by IL-113 and unchanged by bFGF.
Growth of normal kidney fibroblasts was unaffected by bFGF and
inhibited by IL-lp. We conclude that compared to normal fibroblasts,
fibrosis-derived renal fibroblasts have a different cytokine-response pro-
file, are IL-i-dependent, produce IL-i as a paracrine growth factor and do
not proliferate to bFGF, a classical fibroblast growth factor.
Interstitial fibrosis is the predominant pathological lesion lead-
ing to end-stage renal failure in the course of chronic glomerulo-
nephritis. Morphological studies reveal a strong correlation be-
tween the degree of interstitial volume expansion and the decline
in excretory renal function [1, 2]. Renal interstitial fibrosis, similar
to fibrosis in general, is the consequence of fibroblast proliferation
in response to injury or inflammation involving proinflammatory
cytokines as well as growth factors. Fibroblast proliferation is
followed by excessive production of extracellular matrix compo-
nents such as collagen and fibronectin [3].
There is increasing evidence that tubulointerstitial fibroblasts
play a key role in the development of renal interstitial fibrosis
[4—6]. It has been shown, for example, that human interstitial
fibroblasts derived from a kidney with glomerulonephritis and
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interstitial fibrosis have an increased rate in spontaneous prolif-
eration in vitro compared to fibroblasts from normal kidneys [7].
This finding suggests that fibroblasts taken out of a tissue envi-
ronment with active fibrotic processes are intrinsically stimulated
to proliferate. However, the specific factors responsible for spon-
taneous proliferation have not been identified.
Several studies have investigated the effects of cytokines such as
interleukin-1 (IL-i), tumor necrosis factor (TNF), platelet-de-
rived growth factor (PDGF), transforming growth factor beta
(TGF-p), and basic fibroblast growth factor (bFGF) on the
proliferation of dermal fibroblasts [3, 8, 9], synovial fibroblasts
derived from patients with rheumatoid arthritis [10, 11], as well as
that of lung fibroblasts derived from patients with chronic pulmo-
nary diseases [12, 13].
In the present study we investigated transformed renal intersti-
tial fibroblast cell lines established from either a human kidney
biopsy with histologically proven glomerulonephritis and intersti-
tial fibrosis or from a normal kidney. For comparison, human
foreskin fibroblasts were used to study proliferation of normal,
non-transformed fibroblasts. Experiments to test spontaneous as
well as cytokine- (IL-113, bFGF) induced proliferation were
performed. In addition, IL-i receptor antagonist (IL-iRa) was
used to identify a specific role of IL-i in fibroblast proliferation.
Methods
Cytokines
Recombinant human IL-1f3, 108 U/mg, a gift of Dr. Aldo
Tagliabue (Sclavo, Siena, Italy), and recombinant human IL-iRa
(gift of Dr. Daniel Tracey, Upjohn Co., Kalamazoo, MI, USA)
[14} were used. Both cytokines had an endotoxin concentration of
<50 pg/mg. Recombinant human bFGF was a gift from Synergen
Inc. (Boulder, CO, USA).
Cell cultures
Human skin fibroblasts were prepared from infant foreskin
tissue samples and cultured in RPMI 1640 (Sigma, St. Louis, MO,
USA) supplemented with 2 mtvi L-glutamine (Sigma), 10 mM
HEPES (Sigma), 100 U/mI penicillin, 100 ig/ml streptomycin
(Gibco, Grand Island, NY, USA), and 10% (vol/vol) Serum Plus®
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serum supplement (JRH Biosciences, Lenexa, KS, USA). Skin
fibroblasts were grown to confluence in RPMI containing 10%
Serum Plus in 75 cm2 tissue culture flasks (Costar, Cambridge,
MA, USA). Skin fibroblasts were rinsed with 10 mri PBS and
treated with 0.05% trypsin and 0.1% EDTA (Gibco). Trypsiniza-
tion was stopped by the addition of 10% Serum Plus. Skin
fibroblasts were studied during passages 5 to 20.
Human renal interstitial fibroblasts were either obtained from a
kidney biopsy with histologically proven glomerulonephritis and
interstitial fibrosis [7] or from a normal human kidney. The
histological diagnosis was membranoproliferative glomerulone-
phritis with tubular dystrophy and interstitial fibrosis. The control
cell line was established from a donor kidney which was prepared
for kidney transplantation but could not be transplanted because
of severe arteriosclerosis of the recipient. The histology showed
no signs of glomerular or interstitial injury or fibrosis. Several
specimens of the medullary part of the biopsy cylinder or the
normal renal tissue were added to petri dishes covered with tissue
culture medium (DMEM, Sigma) supplemented with 2 mrvi
L-glutamine, 100 U/mI penicillin, 100 g/ml streptomycin and
20% (vol/vol) fetal calf serum, FCS (HyClone Inc., Logan, UT,
USA). Cells growing out from the tissue specimens were identi-
fied as epithelial cells and fibroblasts by morphologic criteria and
immunophenotyping [15, 16]. The mixed cultures were treated
with tlypsin (0.05%)/EDTA (0.1%) and subcultured in limiting
dilutions in DMEM 20% FCS. Single cell type colonies were
surrounded by siliconized glass rings and trypsinized. Fibroblast
clones as identified by morphologic criteria were subcultured in
DMEM, 10% FCS.
Clones of these early passage human renal fibroblasts were
immortalized by transfection with the SV4O plasmid pSV3gpt [17].
Stable cell lines of SV4O immortalized fibroblasts were obtained
by repeated subcloning of transfected cells [18]. The renal fibro-
blast cell lines are comparable to the parental non-transformed
interstitial fibroblasts as indicated by similar morphology, an
unchanged expression pattern of collagens, fibronectin, laminin
and vimentin as well as the negative immunostaining for cyto-
keratin, desmin and factor VIII in both cell lines [18].
The renal fibroblast cell lines were maintained in RPMI
supplemented with 2 m L-glutamine, antibiotics and 10% FCS,
and studied during passages 15 to 30.
Proliferation assay
Skin fibroblasts were maintained in media supplemented with
Serum Plus and renal fibroblasts in media supplemented with
FCS. In all experiments, however, a mixture of equal portions of
FCS and Serum Plus as a serum supplementation was used. The
50/50 serum mixture is called "serum" in this report.
Fibroblasts were washed in PBS, trypsinized (0.05% trypsin,
0.1% EDTA) for two minutes at 37°C, diluted in RPMI contain-
ing 10% serum and centrifuged for 10 minutes at 250 X g to
inactivate the trypsin. Cell pellets were resuspended in RPMI
containing 10% serum and quadruplicate samples of 200 p1
aliquots of cell suspension were added to 96-well flat bottom
microtiter plates (Costar). The cell number added to wells was
adjusted to approximately 2500 skin fibroblasts per well and
approximately 10,000 renal fibroblasts per well. For the following
sets of experiments the number of experiments performed is given
in the Figure legends.
In order to compare the effect of high (10%) to low (1%) serum
supplementation, 180 p1 of culture media were replaced in half of
the wells of a microtiter plate after 24 hours by an equal volume
of RPMI resulting in a final serum concentration of 1%. Fibro-
blasts were then incubated for 1, 3, 5, and 7 days.
In a second series of experiments we tested the effect of IL-1f3,
bFGF, and IL-iRa on fibroblast proliferation. In these experi-
ments, fibroblasts were divided into two aliquots after trypsiniza-
tion, one aliquot in RPMI containing 10% serum and a second
aliquot in RPMI containing 10% serum and IL-iRa (1 g/ml).
Cell suspensions were added to microtiter plates (200 pl per well).
After 24 hours of incubation, 160 p1 of culture media per well was
replaced by equal amounts of RPMI with or without IL-iRa (1
ig/ml) giving a serum concentration of 2%. After another 24
hours, 100 p1 of the media was replaced by 100 pl of either RPMI
alone or RPMI with various concentrations of IL-lp, bFGF, or
IL-iRa. The final serum concentration in these experiments was
1%. The day of stimulation was assigned as day 0. Fibroblasts
were then incubated for 1, 3, 5, and 7 days or as otherwise
indicated in the Figure legends.
The turnover of the tetrazolium salt XTT, 3,3'-[l-[(phe-
nylamino) carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)-ben-
zenesulfonic acid, hydrate, sodium salt (Polyscience, Inc. War-
rington, PA, USA) into its water soluble formazan product was
used to determine fibroblast proliferation [19]. Only viable cells
reduce XTF metabolically due to mitochondria activity. In order
to enhance the sensitivity of this assay, the electron-coupling
agent phenazine methosulfate (PMS) (Sigma) was used [19]. The
assay was performed as follows: After the indicated time periods
of fibroblast incubation, 50 Ll of RPMI containing 1 mg/mI XTT
and 0.025 mrvt PMS were added to each well of quadruplicate
samples and incubated for four hours at 37°C. Then absorbance
was read at 450 nni using an ELISA reader.
To validate the measurement of XTF turnover as a marker of
cell proliferation, absorbance at 450 nm was compared to cell
counts in parallel incubations in the same microtiter plate. In
these experiments, fibroblasts were washed in PBS, trypsinized,
resuspended in RPMI and counted using a Neubauer hemacytom-
eter. The mean absorbance at 450 nm of quadruplicate samples
was plotted against the mean of duplicate cell counts per well (Fig.
1). We further tested the influence of increased serum concentra-
tions and IL-1f3 on the results of the X1T assay.
Radioimmunoassay for human fibronectin
A radioimmunoassay was developed using purified human
serum fibronectin (Becton Dickinson Labware, Bedford, MA,
USA) and a monospecific polyclonal rabbit serum raised against
human serum fibronectin (Becton Dickinson). Five microgram of
purified fibronectin (>85% pure by SDS PAGE) were labeled
with 125lodine by the chloramine T method. After separation on a
G-15 column (Pharmacia), the specific activity of 11 Ci/g was
obtained. A standard curve was constructed based on a compet-
itive binding of radiolabeled fibronectin with a 1:50,000 dilution of
rabbit anti-human fibronectin. Immunoprecipitation employed
sheep anti-rabbit IgG (Ventrix, Billerica, MA, USA) in 6%
polyethylene glycol (6,000, Sigma). A binding of 1251-fibronectin
of 95% was defined as detection limit which was approximately 2
ng/ml. The fibronectin content in culture medium with 1% FCS
was below the detection limit of the fibronectin RIA.
To determine the synthesis of fibronectin by renal fibroblasts in
culture, approximately 200,000 cells per well were added to
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Fig. 1. Correlation between cell numbers and XTT assay for fibroblasts
derived from a kidney with kidney fibrosis (D), a normal kidney (0), or
normal skin (•). Quadruplicate samples of serial dilutions of fibroblasts
were incubated in 1% serum for two days. Then XTF assay was per-
formed. Fibroblasts from parallel incubations were trypsinized and
counted in a Neubauer hemacytometer. The mean absorbance (450 nm) of
quadruplicate samples (horizontal axis) are plotted against the mean of
duplicate cell counts per well (vertical axis). The graph shows the
combined data of three experiments performed on three different cultures
of fibroblasts performed over several weeks.
24-well culture plates and incubated in serum-free culture me-
dium with and without IL-1f3 or IL-iRa. After three days of
incubation, fibroblasts were washed in PBS, trypsinized and
counted in a Neubauer hemacytometer. At this time, fibroblasts
were subconfluent yielding cell counts of 300,000 to 400,000 per
well. Fibroblasts in parallel duplicate incubations were lysed by
three freeze-thaw cycles, and total fibronectin production was
measured in cell lysates by RIA and corrected for cell numbers.
Statistics
Individual experiments were performed in quadruplicates and
data were averaged (mean SD). Results of several independent
experiments were combined by expressing averaged values as
percent (mean 5EM) of appropriate controls. Significant differ-
ences were assessed using one factor ANOVA analysis. Post-hoc
method of data evaluation was Fisher's PLSD test.
Results
Correlation between cell counts and XTT assay
Figure 1 shows the correlation between absorbance at 450 nm
after four hours of incubation with XYT/PMS and the number of
counted cells. A doubling in XTT turnover is parallel with a
doubling in cell numbers counted in each cell line. However, to
obtain the same rate of XTT turnover, approximately five times as
many renal fibroblasts (similar for both kidney cell lines) than skin
fibroblasts are needed. The correlation was high in fibrosis-
derived renal fibroblasts (r2 = 0.894), in normal renal fibroblasts
(r2 = 0.805), and in normal skin fibroblasts (r2 = 0.835). These
data suggest that renal fibroblasts have a lower mitochondrial
activity or less mitochondria per cell than skin fibroblasts. This
assumption is supported by the difference in cell size and mor-
phology as demonstrated in the micrographs (Fig. 2) showing that
fibrosis-derived kidney fibroblasts are smaller than skin fibro-
blasts. Fibroblasts from a normal kidney were morphologically not
distinguishable from fibrosis-derived kidney fibroblasts (not
shown). Furthermore, when renal fibroblasts were stimulated with
either increasing concentrations of serum or cytokines such as
IL-1J3, changes in XTT turnover were paralleled by changes in cell
numbers along the curves shown in Figure 1. Thus, changes in
total mitochondrial activity do reflect changes in cell numbers.
These data prove that the XTF assay is a reliable test to determine
fibroblast proliferation.
Influence of serum concentration on fibroblast proliferation
To evaluate the effect of exogenous growth factors, the different
fibroblasts were incubated for 1, 3, 5, and 7 days in RPMI
supplemented with either 10% or 1% serum (Fig. 3). Compared
to day 1, proliferation of fibrosis-derived renal fibroblasts in-
creased over time and reached 206 12% after five days in 10%
serum and 178 10% in 1% serum. Similar results were obtained
for normal renal fibroblasts after five days (173 21% in 10%
serum; 176 11% in 1% serum). Differences between high (10%)
and low (1%) serum concentration were not significant for the two
renal cell lines. In contrast, skin fibroblasts proliferated only in the
presence of 10% serum reaching 265 37% on day 5 compared
to day 1. In the presence of 1% serum, growth of skin fibroblasts
was less (day 5, 128 8%; P < 0.01) compared to the prolifera-
tion in 10% serum. Therefore, skin fibroblasts proliferate primar-
ily under conditions of high serum content.
Effect of IL-i receptor blockade on spontaneous proliferation of
fibro blasts
In the presence of 1% serum, proliferation of fibrosis-derived
and normal renal fibroblasts reached maximal cell numbers within
five days of incubation with 178 10% and 176 11%,
respectively. As shown in Figure 4, the spontaneous proliferation
of fibrosis-derived renal fibroblasts was completely inhibited in
the presence of IL-iRa on days 3 through 7 (P < 0.01). In
contrast, the growth of normal renal fibroblasts in 1% serum was
not reduced by IL-iRa, and cell numbers of skin fibroblasts did
not change and were not affected by IL-iRa under these condi-
tions (Fig. 4). In the presence of 10% serum, neither one of the
three cell lines was significantly reduced by the addition of IL-iRa
(1 gIml) (data not shown). In additional experiments, fibroblasts
were incubated in 1% serum with and without increasing concen-
trations of IL-iRa. As demonstrated in Figure 5, proliferation of
fibrosis-derived renal fibroblasts as determined after seven days of
incubation was reduced by IL-iRa at 0.1 g/ml by 10 2% (P <
0.05), at 1 pg/mI by 22 8% (P < 0.005), and at 10 g/ml by 34
4% (P < 0.005). In contrast, none of the IL-iRa concentrations
used had a significant inhibitory effect on the proliferation of
normal renal fibroblasts or skin fibroblasts.
Comparison of IL-i f3 and bFGF-induced fibroblast proliferation
Renal and skin fibroblasts were stimulated for four days with
various concentrations of IL-113 (Fig. 6A) or bFGF (Fig. 6B).
Compared to control incubations in 1% serum, addition of IL-13
enhanced the proliferation of fibrosis-derived renal fibroblasts. At
0.1 ng/ml, there was an increase by 26 5% (P < 0.01), and at I
ng/ml by 34 5% (P < 0.001). IL-113 concentrations of 10 nglml
did not further increase proliferation. The addition of exogenous
IL-113 had an opposite effect on normal renal fibroblasts. At 0.1
0.5 1.0 1.5 2.0 2.5
XTT assay, absorbance at 450 nm
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Fig. 2. Photomicrographs (x 100) of non-confluent fibrosis-derived renal fibroblasts (A) and normal skin fibroblasts (B) growing in culture flasks in RPMI
containing 10% seiwn.
Fig. 3. Influence of serum concentration on
fibroblast proliferation. Fibroblasts derived from
kidney fibrosis, normal kidney (approximately
10,000 cells per well each) and normal skin
(approximately 2,500 cells per well) were
incubated in RPM! containing 10% (closed
symbols) or 1% serum (open symbols) for 1, 3,
5 and 7 days. Results of the XTT assay
(absorbance at 450 nm) obtained on days 3—7
are expressed as per cent of that on day 1.
Error bars represent the mean SEM of 4
separate experiments. Reducing serum
concentration from 10% to 1% has no effect on
proliferation of renal fibroblasts but reduces
growth of skin fibroblasts significantly (**P <
0.01 for 10% vs. 1% on days 3 to 7).
ng/ml !L-1/3, proliferation was inhibited by 12 1% (P < 0.01)
and with 1 nglml by 21 3% (P < 0.01). IL-113 had a minimal
enhancing effect on skin fibroblast proliferation. In response to 1
to 10 ng/ml of !L-lp, proliferation was enhanced by 12 3% (P
<0.05) compared to spontaneous growth in 1% serum alone. In
contrast, bFGF at concentrations of 10 and 100 ng/ml enhanced
proliferation of skin fibroblasts by 51 11% (P < 0.01) and 71
13% (P < 0.01), respectively, but had no effect on fibrosis-derived
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Fig. 5. Dose response of IL-IRa-dependent inhibition of spontaneous fibro-
blast proliferation. Fibroblasts derived from kidney fibrosis (S), normal
kidney (s), and normal skin (open symbols) were incubated in RPMI
containing 1% serum (control) and increasing concentrations of IL-iRa.
After 7 days of incubation, XTI' assay was performed. Results (absor-
bance at 450 nm) are expressed as percent of control incubations for 7
days in 1% serum. Error bars depict the means SD of quadruplicate
samples. IL-IRa concentrations of  0.1 gIml inhibit proliferation of
fibrosis-derived renal fibroblasts (*P < 0.05, < 0.005) but had no
effect on proliferation of cells derived from a normal kidney or normal
skin.
C Normal skin
Fig. 4. Effect of IL-iRa on spontaneous
pmliferation of fibroblasts. Fibroblasts derived
from kidney fibrosis, normal kidney or normal
skin were incubated in RPMI containing 1%
serum for 1, 3, 5, and 7 days in the presence
(open symbols) or absence (closed symbols) of
1 Wml IL-iRa. XT assay was performed
after the indicated time periods. Results
(absorbance at 450 nm) obtained on days 3
through 7 are expressed as percent of those
obtained on day 1. The error bars represent the
mean SEM of 4 separate experiments. IL-iRa
reduces proliferation of fibrosis-derived renal
fibroblasts but had no effect on normal renal or
D skin fibroblasts (*P < 0.01, **D < 0.001) onays days 3 through 7.
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IL-i 13-induced fibroblast proliferation is inhibited by IL-IRa
The IL-1/3-induced proliferation of fibrosis-derived renal fibro-
blasts and skin fibroblasts was completely inhibited (P < 0.01) by
a 1000-fold molar excess of IL-iRa (data not shown). Additional
experiments were performed to determine the 50% inhibitory
concentration (IC50) of IL-IRa for IL-113-induced proliferation
(Fig. 7). In culture media containing 1% serum, fibrosis-derived
renal fibroblasts were stimulated for seven days with 50 nglml
IL-1p in the presence of increasing molar excess of IL-I Ra. The
IC50 was reached at an eightfold molar excess of IL-iRa over
IL-113.
IL-iRa enhances fibronectin production by renal fibroblasts
**
Fibrosis-derived as well as normal renal fibroblasts were incu-
80 bated in 24 well plates in serum-free tissue culture medium for
three days in the presence or absence of various concentrations of
IL-113 or IL-iRa (Fig. 8). The fibronectin production per 300,000
fibrosis-derived renal fibroblasts increased dose-dependently in
the presence of IL-iRa. Compared to controls, 7.42 0.88 .tg,
fibronectin production was significantly enhanced in the presence
** of 100 ng/ml IL-iRa to 13.66 2.17 jig (P < 0.05), with 1 jig/ml
to 16.42 2.84 (P < 0.01), and with 10 jig/ml to 14.45 0.92 (P60 < 0.05). In contrast, fibronectin production by normal renalControl 0.01 0.1 1 10 fibroblasts was unaffected by IL-IRa. IL-1/3 had no effect on
fibronectin production by fibrosis-derived renal fibroblasts. When
IL-Ra, pg/mi incubated with 100 nglml of IL-1/3, there was a non-significant
increase in fibronectin production by normal renal fibroblasts.
or normal renal fibroblasts. The bFGF effect on skin fibroblasts
was not inhibited by the addition of IL-iRa (1 ig!ml) (data not
shown).
Discussion
The data presented in this report demonstrate that fibroblasts
derived from a kidney with histologically proven interstitial fibro-
sis as well as from a normal kidney proliferate spontaneously in
vitro in the presence of limited serum-derived growth factors.
Although the increased spontaneous proliferation of both renal
cell lines could be partially due to the transformation itself, an
important new observation is that the spontaneous growth of only
fibrosis-derived renal fibroblasts but not that of normal renal cells
was inhibited by blocking IL-I receptors using IL-iRa. These data
suggest that the in vitro proliferation of fibrosis-derived renal
fibroblasts is IL-i-dependent. Furthermore, exogenous IL-1J3 acts
as a growth factor for the fibrosis-derived fibroblasts but not for
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Fig. 7. Inhibition of IL-i 13-induced fibroblast proliferation by IL-iRa. Fi-
brosis-derived renal fibroblasts were stimulated with 50 nglml IL-113 in
RPM! containing 1% serum in the presence or absence of 0.02- to
1000-fold molar excess of IL-iRa. After 7 days of incubation, XTF assay
was performed. Results are given in percent of controls (50 nglml IL-1f3
only), means SD of quadruplicate samples. The IC50 (indicated by the
broken lines) of IL-iRa for IL-1/3-induced proliferation was reached at a
eightfold molar excess of IL-IRa.
those from a normal kidney. In contrast, IL-1f3 inhibits the
spontaneous growth of transformed normal renal fibroblasts. By
comparison, the proliferation of primary human skin fibroblasts
was stimulated by IL-1f3, bFGF and growth factors provided by
serum. IL-i /3 was the weakest and serum the strongest growth-
promoting factor for skin fibroblasts.
Although we studied proliferation in vitro, by extension we
speculate that an active fibrotic process in the kidney renders
interstitial fibroblasts into IL-i-producing cells using this cytokine
Fig. 6. Dose response of IL-i /3 and bFGF-
induced fibroblasts proliferation. Fibroblasts
derived from kidney fibrosis (S), normal kidney
(•), and normal skin (0) were incubated in
RPM! containing 1% serum in the presence or
absence of 0.1, 1 and 10 ng/ml IL-113 (A) or 1,
10, and 100 nglml bFGF (B). XTT assay was
performed after 4 days of incubation. Results
(absorbance at 450 nm) are expressed as
percent of controls (1% serum for 4 days). The
error bars represent the mean SEM of 5
experiments. IL-1/3 dose-dependently enhances
proliferation of fibrosis-derived renal fibroblasts
and skin fibroblasts but inhibits growth of
normal kidney fibroblasts. High doses of bFGF
(10 to 100 nglml) enhance proliferation of skin
fibroblasts but have no effect on neither renal
fibroblast cell line. Asterisks indicate P values
compared to control (1% serum): * < 0.05,
< 0.01.
as a paracrine growth factor. In an accompanying paper, we show
that normal as well as fibrosis-derived renal fibroblasts have
increased gene expression for IL-la and IL-1f3, detectable IL-i
protein synthesis (200 to 300 pg of IL-la per 200,000 renal
fibroblasts), and comparable numbers of IL-i receptors (600 to
1000 receptors per cell). Therefore, the IL-i-dependent prolifer-
ation of fibrosis-derived fibroblasts is most likely regulated at the
level of IL-i responsiveness, and not at the level of IL-i produc-
tion. It will be necessary to show that IL-i activates signal
transduction pathways 20, 211 in fibrosis-derived fibroblasts dif-
ferently from those in normal renal fibroblasts.
Increasing the serum concentration from 1% to 10% or adding
bFGF to the cultures containing 1% serum induced growth of
primary skin fibroblasts, but had no enhancing effect on the
proliferation of the two renal cell lines. Therefore, renal fibro-
blasts appear to be refractory to mitogens which commonly
stimulate the growth of fibroblasts of other origin. As the prolif-
eration of normal renal fibroblasts is neither effected by increasing
the serum concentration nor by adding IL-iRa, these cells seem to
depend on yet unknown growth factors different from IL-i.
As the SV4O transformation itself may have affected both renal
cell lines it is difficult to draw conclusions from different responses
seen in primary skin fibroblasts compared to transformed renal
fibroblasts. We are also aware of the possibility that differences
between the two transformed renal fibroblast cell lines could, on
a theoretical basis, result from the site of insertion of the viral
genes into the cellular genome. However, differences in the
response of the two transformed renal fibroblast cell lines may
reflect functional changes caused by the inflammation in the
kidney of origin. IL-1/3 stimulates growth of fibrosis-derived renal
cells and has a moderate inhibitory effect on the proliferation of
normal kidney fibroblasts. Furthermore, the addition of IL-iRa
inhibited growth and enhanced fibronectin production by fibrosis-
derived renal fibroblasts. In contrast, proliferation and fibronectin
production of transformed fibroblasts derived from a normal
kidney were not influenced by IL-iRa. Taken together, these data
suggest that the overall responsiveness of renal interstitial fibro-
blasts to IL-i may be different in acute compared to chronic
inflammatory processes. In acute inflammation, the presence of
proinflammatory cytokines in the kidney may cause programmed
A B
** **
c3 *
**
**
--I
- 4
..*
.180
IL..
0
140 fl
::°
Control 0.1 1 10 Control 1 10 100
IL-i , ng/ml bFGF, ng/mI
0
o.
0
q)
11)0.
00
-40
00o
00
a)0.
180
140
100
60
100 I
90
80
70
60
Lonnemann et al: Interleukin-1 and human kidney fibroblasts 843
-0-- control
-•-IL-1
-A- IL-iRa •*
Fig. 8. Effect of IL-IRa and IL-1/3 on
fibronectin production by renal fibroblasts.
Fibroblasts derived from kidney fibrosis or
normal kidney were incubated for 3 days in 24
well plates in serum-free culture medium in the
presence and absence of the indicated
concentrations of IL-113 or IL-iRa. Total
fibronectin production was determined in cell
lysates after three freeze-thaw cycles.
Fibronectin production is depicted in
microgram per 300,000 renal fibroblasts. Mean
SEM of 3 experiments; *JJ < 0.05, ''P <
0.01.
cell death of interstitial fibroblasts whereas in chronic inflamma-
tion, the same cytokines may have an opposite effect by inducing
proliferation. Further studies are necessary to describe the mech-
anisms and factors which are responsible for the different IL-i
response of fibrosis-derived compared to normal renal fibroblasts.
Our data confirm previous studies describing an increased
proliferation rate of interstitial fibroblasts derived from human
kidneys with histologically proven fibrosis compared to normal
skin fibroblasts [7]. Kidney fibroblasts, similar to skin fibroblasts,
differentiate along a lineage from mitotic to postmitotic cell types
[22, 23}. Each cell type has a characteristic growth cycle. The cell
cycling time for mitotic renal fibroblasts derived from fibrotic
kidneys was significantly reduced compared to similar cells de-
rived from normal kidneys [23]. The conclusion drawn from those
studies was that the hyperproliferative response of fibrotic renal
fibroblasts could be, in part, attributed to reduced cell cycle time.
Although fibroblasts derived from kidneys with interstitial
fibrosis are hyperproliferative in vitro, the histology of kidneys
from which they were taken shows considerable matrix deposition
with variable numbers of infiltrating mononuclear cells, and in
most cases, only few interstitial fibroblasts [1, 4]. As the differen-
tiation from a mitotic to a postmitotic state progresses, there is an
increased production of extracellular matrix [4]. The progression
of fibroblast proliferation and differentiation into matrix-produc-
ing cells seems to be an important issue in the development of
fibrosis in a variety of chronic, post-inflammatory diseases in
different organs including the lung [24, 25] and synovial tissue [26,
27].
In the data presented, IL-iRa reduced the proliferation and
enhanced the fibronectin production of fibrosis-derived renal
fibroblasts in vitro. Whether endogenous IL-iRa plays a regula-
tory role in the fibrotic kidney remains speculative. However, the
early phases of an interstitial fibrotic process in the kidney is
accompanied by the infiltration of monocytes/macrophages and
lymphocytes [28, 29]. Monocytes/macrophages produce large
amounts of IL-iRa in response to multiple stimuli including IL-i,
TNF-a, and TGF-/3 [20, 30, 31]. Monocytes/macrophages as well
as T helper cells, the predominant lymphocyte subset in the
mononuclear cell infiltrate, produce a variety of cytokines and
growth factors, for example TGF-p [32], IL-4 and IL-b [33, 34].
TGF-p has been shown to be antiproliferative for many cell types
including fibroblasts and glomerular mesangial cells [32, 35],and
this activity is possibly due to the induction of IL-Ra [31, 36]. A
subtype of T helper lymphocytes, the Th2 cells, produces IL-4,
IL-b and IL-13, cytokines which suppress IL-i but induce IL-iRa
production by monocytes/macrophages [37, 38]. Taken together,
recent studies including the present one support the concept that
blocking IL-i activity, possibly due to increased IL-iRa produc-
tion, may lead to increased synthesis of matrix and decreased
production of collagenase, resulting in interstitial fibrosis.
The observation that proliferation of fibroblasts derived from
diseased organs is increased by paracrine production of growth
factors such as IL-i is not restricted to fibroblasts of kidney origin.
For example, synovial fibroblasts from patients with rheumatoid
or inflammatory arthritis spontaneously produce mitogens includ-
ing bFGF and IL-i [39], whereas nonrheumatoid synovial cells or
cells from osteoarthritis patients did not [39, 40]. Therefore,
increased in vitro proliferation of fibroblasts due to paracrine
production of mitogenic cytokines seems to be related to an active
fibrotic process and is not organ specific.
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